Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium.
Csaky
Karl G
KG
Ophthalmic Unit, DCRI, Duke University Medical Center, Durham, NC 27710, USA. karl.csaky@duke.edu
Richman
Elaine A
EA
Ferris
Frederick L
FL
D001284:Atrophy; D020256:Choroidal Neovascularization / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000592:standards*; D003930:Diabetic Retinopathy / Q000188:drug therapy; D023381:Endpoint Determination; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy; D009316:National Institutes of Health (U.S.); D009885:Ophthalmology / Q000592:standards*; D017060:Patient Satisfaction; D010857:Pigment Epithelium of Eye / Q000473:pathology; D011358:Product Surveillance, Postmarketing; D012107:Research Design / Q000592:standards*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D014792:Visual Acuity / Q000502:physiology